AUTHORS
Kimberly Newman, MD, Jayasree Krishnan, MD, MSPH2, Janine Joseph, MS, MBA3, Hemn Mohammadpour, DVM, PhD4, Joseph Tario, PhD5, Hamza Hassan, MD6, Philip L. McCarthy, MD7, Jens Hillengass, MD, PhD8
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Background
Responses and outcomes in multiple myeloma (MM) remain heterogeneous despite improved treatments and comprehensive risk stratification. Markers such as high-risk cytogenetic abnormalities (HRCA) and minimal residual disease (MRD) status have been validated, but do not account for the host immune fitness that mediates response to modern immune-directing therapies. The prognostic value of readily obtainable peripheral blood (PB) immunophenotyping at diagnosis is not established. We hypothesize that the pre-treatment PB balance between exhausted and non-exhausted T cells would be associated with clinical outcomes.
Methods
We identified 221 patients with NDMM who underwent PB immunophenotyping at diagnosis prior to receipt of any anti-myeloma therapy. Flow cytometry quantified exhausted and non-exhausted CD4+ and CD8+ T cell populations, expressed as a percentage of total lymphocytes; the ratio of exhausted to non-exhausted cells was calculated within each of the CD4+ and CD8+ compartments. Exhausted T cells were defined as those that expressed ≥ 2 of the following: PD1, TIGIT, LAG3, TIM3.
Cytogenetic risk (high-risk [hR] vs standard-risk [sR] according to the IMS-IWMG 2024 criteria) and MRD status by flow cytometry at best response were extracted from clinical records. Descriptive statistics are presented as means (SD) or frequencies (%). Age-adjusted Cox proportional hazards models assessed the association of immune markers, MRD status, cytogenetic risk with overall survival (OS). Hazard ratios (HR) for immune markers correspond to a two-fold increase in the marker. A two-sided p<.05 was considered significant. Analyses were performed in SAS 9.4 (Cary, NC).
Results
Mean age at immunophenotyping was 67.6 (SD 10.2) years with 112 (50.7%) female patients. Self-reported race was White in 184 (83.3%), Black in 23 (10.4%), and other in 14 (6.3%). Heavy/light chain subtype was IgG in 121 (54.8%), IgA in 44 (19.9%), light chain only in 47 (21.3%), and other in 9 (4.1%). 60 (27.2%) patients were hR, 139 (62.9%) patients were sR, and cytogenetic information was unavailable in 22 (10.0%). MRD at best response was positive in 15 (6.9%), negative in 129 (58.9%), and not assessed in 77 (34.3%).
In age-adjusted models, a two-fold higher proportion of CD4+ non-exhausted T cells was associated with significantly longer OS (HR 0.66; 95% CI 0.49–0.89; p=.0068), and a two-fold higher CD4+ exhausted: non-exhausted ratio was associated with significantly shorter OS (HR 1.41; 95% CI 1.09–1.83; p=.0087). CD4+ exhausted cells alone did not reach significance (HR 1.22; 95% CI 0.82–1.81; p=.3347). As a percentage of lymphocytes, exhausted CD4+ cells were lower in hR than sR (4.5% vs 5.8%; p=.0234). However, when calculated as a percentage of total CD4+ cells (10.5% vs 11.8%; p=.2001) there was no significant difference noted in the exhausted: non-exhausted ratio (p=.1527). This is likely attributable to greater CD4+ abundance in sR. No CD8+ parameter was significantly prognostic. Median follow-up was 2 years 10 months. Median OS was not reached.
MRD positivity at best response was associated with a markedly higher hazard of death (HR 29.2; 95% CI 4.19–204.2; p=.0007), though the extremely wide confidence interval reflects only 15 MRD-positive patients and limits interpretability. MRD assessment was also not consistently performed first-pull from the bone marrow with potential false-negatives related to hemodilution. HRCA were not significantly associated with OS in this cohort (HR 1.62; 95% CI 0.84–3.11; p=.1497).
Conclusions
In this cohort of 221 treatment-naive patients with NDMM, the peripheral blood CD4+ compartment demonstrated prognostic correlation with OS showing that preserved non-exhausted CD4+ T cells were protective, and a higher exhausted: non-exhausted CD4+ ratio had an adverse effect, even after adjustment for age. These associations were observed in a cohort in which HRCA alone did not significantly discriminate survival. Median OS was not reached which could suggest that the follow-up was not long enough for tumor genomics to exert an effect or that host T cell fitness contributes prognostic information not captured by tumor genomics. Findings are hypothesis-generating and limited by the observational single-cohort design and heterogeneous treatment exposure. Validation with standardized exhaustion marker panels, multivariable adjustment including treatment and ISS/R-ISS stage is underway.
DISCLOSURES
Kimberly Newman, MD: No relevant conflicts of interest to declare.